Developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders.
Developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders.
Drug Discovery📍 South San Francisco, CAFounded 2014
Current Valuation
$625M
as of 2020-Q3
PRIVATE
QL Price
$625M
0% vs last round
QuantLogix's current estimate for Encoded Therapeutics, published 2026-09-27 — in line with the last disclosed round of $625M (2020-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$625M
2020-Q3
weight 0.02
How this price has held up
No round has priced for Encoded Therapeutics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Encoded Therapeutics, 2026-09-27 (298cc12e5fde5262).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Encoded Therapeutics going public?
No. Encoded Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Encoded Therapeutics' valuation in 2026?
Encoded Therapeutics is valued at $625M as of 2020-Q3, set by its Series D ($135M, Jul 2020). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Encoded Therapeutics filed an S-1?
No public S-1 is on file for Encoded Therapeutics.
How much has Encoded Therapeutics raised?
Encoded Therapeutics has raised $298.62M in total, most recently a Series D of $135M in Jul 2020.
Is Encoded Therapeutics publicly traded — can you buy Encoded Therapeutics stock?
No. Encoded Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Encoded Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2014
HQ
South San Francisco, CA
Employees
177
Total Raised
$298.62M
Last Round
Series D — $135M (Jul 2020)
IPO Status
private
Fundraising Status
Series D · $135M · 6y 2mo ago
privateTotal raised $298.62M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$135M
Jul 2020
—
$625M
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
4
3 active · 1 recruiting
Lead phase
Phase 2
most advanced registered study
Focus areas
Dravet Syndrome
Latest trial start
2024-05-14
Name-verified against lead sponsor "Encoded Therapeutics" on ClinicalTrials.gov as of 2026-09-19. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▲ Hiring uptrend
+11% vs 2026-08
Open roles
21
via careers page
Product-build share
52%
engineering, research, product, design
Trajectory
expanding
product-led hiring — 52% of open roles build product; the rest are go-to-market and G&A.
No tracked executive churn; open roles trending up.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Clinical StudiesResearch AreasAssociate Director of Clinical Sciences (Pediatric Neuropsychology)Engineer, Process Sciences – UpstreamSenior Engineer, Process Sciences – Drug ProductSenior Drug Product Engineer
Counted from Encoded Therapeutics's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareBiotechnologyTherapeuticsGenetics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2020-Q3. Refreshed quarterly.